Invest in a Clinical-Stage Psychedelics Leader with a Growing IP Portfolio

Download the company's investor presentation and receive corporate updates.

Investment Highlights

Robust Technology & IP Portfolio

Well-Funded Psychedelic Clinical Trials

Revive Therapeutics has significantly grown its psychedelics presence after acquiring Psilocin Pharma Corp. and partnering with PharmaTher Inc.

In-house IP portfolio covering psilocybin methods and compositions, as well as drug delivery systems, including convenient oral strips.

Raised $20 million in a bought deal offering to fund Phase I clinical trials for psilocybin for methamphetamine use disorder and other research.

Partnerships with Leading Companies & Institutions

Unique Business Model & Go-to-Market Strategy

Partnership with the University of Wisconsin to conduct clinical trials, as well as PharmaTher Inc. (CSE: PHRM) to develop novel treatments.

Targeting FDA designations, such as Orphan, Fast Track and Breakthrough Therapy Status in order to accelerate commercialization.

Download the Investor Presentation & Receive Updates

Copyright © 2020. All rights reserved.